|
Follow-up of a French national cohort of melanoma stage IV and unresectable stage III patients, MelBase. |
|
|
No Relationships to Disclose |
|
|
|
Research Funding - Roche Pharma AG (Inst) |
Travel, Accommodations, Expenses - Roche Pharma AG |
|
|
Consulting or Advisory Role - Roche Pharma AG |
Research Funding - Roche Pharma AG |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - MSD |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; MSD; Roche Pharma AG |
Research Funding - Roche Pharma AG (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Roche Pharma AG |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Roche Pharma AG |
Travel, Accommodations, Expenses - Abbvie; Janssen-Cilag; Novartis |
|
|
Honoraria - Abbvie; Bristol-Myers Squibb; Pfizer |
Consulting or Advisory Role - Abbvie; Pfizer |
Other Relationship - Novartis; Roche Pharma AG |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; Roche Pharma AG |
Consulting or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Roche Pharma AG |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; GlaxoSmithKline; Roche Pharma AG |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; MSD; Novartis |
Travel, Accommodations, Expenses - Roche |